Seat No: _____

Enrollment No: _____

PARUL UNIVERSITY FACULTY OF PHARMACY

B. Pharm. Summer 2022 - 23 Examination

Semester: 8 Date: 17/04/2022

Subject Code: BP805ET Time: 10:00am to 1:00pm

Subject Name: Pharmacovigilance Total Marks: 75

| | | ns: |
|--|--|-----|
| | | |
| | | |

- 1. Figures to the right indicate maximum marks.
- 2. Make suitable assumptions wherever necessary.

c) Anaphylaxis associated with penicillin

| Q.1 | Multiple Choice Questions (MCQs) (1 Mark Each) | | (20) | | |
|-----|---|---|-------------|--|--|
| 1. | Pharmacovigilance Continue throughout:- | | | | |
| | a) Post marketing surveillance | b) Pre & post marketing surveillance | | | |
| | c) Pre marketing surveillance | d) None of the above | | | |
| 2. | Pharmacovigilance Programme of India started in, | | | | |
| | a) 2009 | b) 2010 | | | |
| | c) 2005 | d) 2012 | | | |
| 3. | Serious Adverse Event | | | | |
| | a) Result in death | b) Life threatening | | | |
| | c) Disability | d) All of the above | | | |
| 4. | Type I ADR reactions is | | | | |
| | a) Caused when T-cells bind to a specific antigen | b) caused by tissue injury | | | |
| | c) IgE mediated | d) Caused by cytotoxic antibodies | | | |
| 5. | The incidence ADR is highest in | | | | |
| | a) Children | b) Elderly | | | |
| | c) Women | d) Men | | | |
| 6. | Which of the following reaction is called Augmented adverse drug reactions? | | | | |
| | a) Genetically determined effects | b) Idiosyncrasy. | | | |
| | c) Rebound effect on discontinuation | d) Allergic reactions & anaphylaxis. | | | |
| 7. | Idiosyncrasy is | | | | |
| | a) Type A ADRs | b) Type B ADRs | | | |
| | c) Type C ADRs | d) Type D ADRs | | | |
| 8. | Which of the following terms does not describe an Adv | verse Drug Reaction? | | | |
| | a) Idiosyncrasy | b) Anaphylaxis | | | |
| | c) Teratogenic effect | d) Placebo effect | | | |
| 9. | Which of the following adverse drug reactions would y | ou report to the Medicines and Healthcare | | | |
| | Products regulatory Agency (MHRA) via the yellow card system for reporting? | | | | |
| | a) A patient reports a skin rash after starting a | b) A patient report experiencing dyspepsia | | | |
| | course on amoxicillin capsules. | when they take their indomethacin capsules. | | | |
| | c) A patient complains of a dry irritating cough | d) A patient complains they have experienced | | | |
| | since they have started taking ramipril. | diarrhea since taking azilsartan. | | | |
| 10. | Pharmacovigilance is done for monitoring of | | | | |
| | a) Drug price | b) Unethical practices | | | |
| | c) Drug safety | d) Pharmacology of drug | | | |
| 11. | Which of the following is Type B ADRS? | | | | |
| | a) Hypoglycemia caused by Insulin | b) Dryness of mouth caused by Atropine | | | |
| | c) Anemia in patient with G6PD deficiency | d) Hyperglycemia caused by thiazide diuretics | | | |
| | caused by Primaquine | • | | | |
| 12. | According to Rawlins-Thompson classification Type | D ADR includes | | | |
| | a) Carcinogenesis | b) Bradycardia associated with beta blockers | | | |

d) Opiate withdrawal syndrome

| 13. | is an example of latent adverse drug reactions. | | | | | |
|----------|---|---|------|--|--|--|
| | a) Antibiotic-associated diarrhea | b) Tardive dyskinesia | | | | |
| | c) Serum sickness | d) Severe bronchoconstriction | | | | |
| 14. | Which one of these is a genetically determined adverse drug reactions? | | | | | |
| | a) Addiction | b) Teratogenicity | | | | |
| | c) Carcinogenicity | d) Idiosyncrasy | | | | |
| 15. | What Is the Difference Between An ADE And ADR? | | | | | |
| | a) There may not be a causal relationship between | b) There may be a causal relationship between | | | | |
| | a drug and an ADE, whereas, there is a causal | a drug and an ADE, whereas, there is a causal | | | | |
| | link between a drug and an adverse drug reaction. | link between a drug and an adverse drug | | | | |
| | | reaction. | | | | |
| | c) There may not be a causal relationship between | d) There may not be a causal relationship | | | | |
| | a drug and an ADE, whereas, there is not a causal | between a drug and an ADE, whereas, there is | | | | |
| | link between a drug and an adverse drug reaction. | a causal link between a drug and an adverse | | | | |
| | | drug event. | | | | |
| 16. | What Do You Mean By Meddra? | | | | | |
| | a) Medical Data for Regulatory Activities. | b) Medical Dictionary for Regulatory Actions. | | | | |
| | c) Medical Dictionary for Right Activities. | d) Medical Dictionary for Regulatory | | | | |
| | | Activities. | | | | |
| 17. | Name The Regulatory Bodies In Japan? | | | | | |
| | a) European Medicines Agency (EMEA). | b) USFDA | | | | |
| | c) Ministry of Health, Labour and Welfare | d) CDSCO | | | | |
| | (MHLW). | | | | | |
| 18. | 8. Which of the following software's Not used in pharmacovigilance is: | | | | | |
| | a)Oracle Argus Safety | b) PvNET | | | | |
| | c) Argus | d)DigSMap | | | | |
| 19. | What is ICSR reporting? | | | | | |
| | a) Individual Co-Case Safety Report | b) Individual Case Safety rate | | | | |
| • • | c) Individual Case Safety Report | d) Individual Case Study Report | | | | |
| 20. | International database called | 1)***** | | | | |
| | a) VigiBase. | b)WHO | | | | |
| | c) Uppsala Monitoring Centre | d)ICH | (20) | | | |
| | 2 Long Answers (any 2 out of 3) (10 Mark Each) | | | | | |
| 1. | Write a short note on Pharmacovigilance Program of In | | | | | |
| 2. | Define ADR and ADE and describe any one causality | assessment methods. | | | | |
| 3. | Describe in detail: ATC, DDD and ICD. | | (25) | | | |
| | Short Answers (any 7 out of 9) (5 Mark Each) | h amas a sui silan a s | (35) | | | |
| 1. | Write the regulatory requirement in Indian and global p | | | | | |
| 2. | Describe the Pharmacovigilance in terms to Pregnancy | and factation. | | | | |
| 3. | č | | | | | |
| 4. 5 | Describe the process of ADR reporting in India. Write a note on AEFI. | | | | | |
| 5. 6. | | | | | | |
| 7. | Describe MedDRA and coding in pharmacovigilance. Write active and passive surveillance method of reporting in Pharmacovigilance. | | | | | |
| 8. | Write active and passive surveillance method of reporting in Pharmacovigilance. Explain case control and cohort study with suitable example. | | | | | |
| 9. | | | | | | |
| 1. | THE a now on communication in I narmacovigitance. | | | | | |